Sermorelin
A 29-amino acid GHRH analogue with a unique clinical history — the only GHRH-class peptide to receive FDA approval. Withdrawn from the market in 2008 for commercial reasons, it remains a key reference compound in growth hormone axis research and anti-aging science.
Unique FDA History Among GHRH Peptides
Sermorelin (brand name Geref) was FDA-approved in 1997 for the diagnosis and treatment of growth hormone deficiency in children. It was voluntarily withdrawn from the US market in 2008 by its manufacturer for commercial reasons — not safety concerns. This makes it the only GHRH-class research peptide with a completed FDA approval and clinical use history, providing a stronger evidence base than unapproved analogues.
Mechanism of Action
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary. It consists of the first 29 amino acids of the 44-amino acid endogenous GHRH — the biologically active fragment that retains full receptor binding activity.
Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary. It is a 29-amino acid fragment of the natural 44-amino acid GHRH, retaining full biological activity.
GHRHR activation stimulates adenylyl cyclase, increasing intracellular cAMP. This activates protein kinase A (PKA), which phosphorylates transcription factors driving GH gene expression.
Unlike exogenous HGH (which provides a constant supraphysiological dose), sermorelin stimulates the pituitary to release GH in pulses — preserving the natural pulsatile pattern that governs downstream IGF-1 production.
Because sermorelin works upstream at the pituitary, the hypothalamic-pituitary axis feedback loop remains intact. Somatostatin (the GH-inhibiting hormone) continues to regulate output, preventing runaway GH elevation.
GH released by the pituitary travels to the liver, stimulating IGF-1 synthesis. IGF-1 mediates most of the anabolic, lipolytic, and tissue-repair effects attributed to GH axis activation.
Research Applications
Adult Growth Hormone Deficiency (AGHD)
Sermorelin was FDA-approved specifically for this indication in children and studied extensively in adults. It stimulates endogenous GH production rather than replacing it, making it mechanistically distinct from recombinant HGH therapy.
Body Composition Research
GH axis activation via sermorelin promotes lipolysis (fat breakdown) and lean mass preservation. Research in older adults with GH deficiency showed improvements in body composition markers including reduced visceral fat and increased lean body mass.
Sleep Architecture
GH is predominantly secreted during slow-wave sleep (SWS). GHRH analogues including sermorelin have been studied for their effects on sleep quality, with research suggesting enhanced SWS and GH pulse amplitude during sleep.
Longevity & Anti-Aging Research
Age-related decline in GH secretion (somatopause) is well-documented. Sermorelin is studied as a means to partially restore youthful GH pulsatility without the risks associated with exogenous HGH, including IGF-1-mediated proliferative effects.
Sermorelin vs. CJC-1295 vs. Ipamorelin
These three peptides are often discussed together as GH-axis research compounds. They differ significantly in mechanism, half-life, and GH release pattern.
| Aspect | Sermorelin | CJC-1295 (w/ DAC) | Ipamorelin |
|---|---|---|---|
| Class | GHRH analogue (29-aa fragment) | GHRH analogue (29-aa + DAC) | Ghrelin mimetic / GHRP |
| Mechanism | GHRHR agonist | GHRHR agonist (extended) | GHS-R1a agonist |
| Half-life | ~10–20 minutes | ~6–8 days (with DAC) | ~2 hours |
| GH release pattern | Pulsatile (physiological) | Sustained / blunted pulse | Pulsatile (synergistic) |
| FDA history | Approved 1997, withdrawn 2008 (commercial) | Never approved | Never approved |
| Cortisol / prolactin | No significant effect | No significant effect | No significant effect |
| Ghrelin-like effects | None | None | Mild appetite stimulation |
| Feedback inhibition | Preserved (somatostatin active) | Partially blunted | Preserved |
| Synergy with GHRP | Yes — commonly stacked with GHRP-2/6 | Yes — commonly stacked with Ipamorelin | Pairs with CJC-1295 |
| Research use | GH deficiency, anti-aging, body composition | Body composition, GH optimization | Body composition, sleep, GH pulse |
Side Effects & Safety Profile
Sermorelin's side effect profile is generally considered favorable compared to exogenous HGH, primarily because preserved somatostatin feedback prevents supraphysiological GH elevation. The following are documented in clinical trial data from the FDA approval period.
Frequency: Common
Redness, swelling, or pain at the injection site. Most common adverse effect in clinical trials.
Frequency: Common
Transient facial flushing reported in some subjects. Typically resolves within 30–60 minutes.
Frequency: Uncommon
Reported in a subset of clinical trial participants. Mechanism unclear — possibly GH-mediated fluid shifts.
Frequency: Uncommon
Postural dizziness reported in some subjects, particularly at higher doses.
Frequency: Uncommon
Less frequent than with GHRP-class peptides. Sermorelin's GHRH mechanism does not activate ghrelin pathways that drive nausea.
Frequency: Rare
GH is counter-regulatory to insulin. Elevated GH can reduce insulin sensitivity. Monitoring recommended in subjects with impaired glucose tolerance.
Frequency: Uncommon
GH-mediated sodium retention can cause mild fluid retention, particularly at higher doses or in older subjects.
Frequency: Expected (pharmacodynamic)
Sermorelin elevates IGF-1 as part of its mechanism. Supraphysiological IGF-1 is associated with theoretical proliferative risks. Baseline and follow-up IGF-1 monitoring is standard in clinical protocols.
Key Research Citations
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.
PubMed PMID: 18046908 ↗Finding: Reviewed sermorelin's advantages over exogenous HGH for adult GH insufficiency — including preserved feedback regulation and lower theoretical IGF-1 excess risk.
Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89–96.
PubMed PMID: 9005978 ↗Finding: Demonstrated that nightly sermorelin injections in elderly men increased GH pulse amplitude and IGF-1 levels, with improvements in body composition and sleep quality.
Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20–39.
PubMed PMID: 8491152 ↗Finding: Foundational review establishing the somatopause concept — age-related decline in GH secretion — and the rationale for GHRH-based interventions in aging research.
Khorram O, et al. Effects of [norleucine27]growth hormone-releasing hormone (GHRH)(1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997;82(12):3957–3960.
PubMed PMID: 9398698 ↗Finding: Studied immunological effects of GHRH analogue administration in aging subjects, finding improvements in immune cell function alongside GH axis activation.
Related Research Guides
Frequently Asked Questions
What is sermorelin?
Sermorelin is a synthetic 29-amino acid peptide that is a fragment of the naturally occurring growth hormone-releasing hormone (GHRH). It acts as a GHRH receptor agonist, stimulating the anterior pituitary to release growth hormone in a pulsatile, physiologically normal pattern. It was FDA-approved in 1997 under the brand name Geref for the treatment of growth hormone deficiency in children.
Is sermorelin FDA-approved?
Sermorelin (Geref) was FDA-approved in 1997 for the diagnosis and treatment of growth hormone deficiency in children. The manufacturer voluntarily withdrew it from the US market in 2008 for commercial reasons (not safety concerns) after recombinant HGH became more widely available. It remains available through compounding pharmacies in the US and is used off-label by some physicians for adult GH insufficiency. It is not currently available as an FDA-approved branded product.
How does sermorelin differ from CJC-1295?
Both are GHRH analogues, but they differ significantly in half-life and GH release pattern. Sermorelin has a short half-life (~10–20 minutes) and produces pulsatile GH release that mirrors the natural pattern. CJC-1295 with DAC has a half-life of ~6–8 days due to its Drug Affinity Complex modification, producing sustained GH elevation that blunts the natural pulsatile pattern. Sermorelin's preserved pulsatility is considered advantageous for maintaining hypothalamic feedback regulation.
What are the research applications of sermorelin?
Sermorelin is studied for: adult growth hormone deficiency (AGHD) and somatopause (age-related GH decline), body composition improvements (lipolysis, lean mass), sleep architecture enhancement (GH is predominantly secreted during slow-wave sleep), and longevity research as an alternative to exogenous HGH. Its preserved feedback regulation makes it a mechanistically cleaner research tool than direct HGH administration.
What is the difference between sermorelin and HGH?
Sermorelin stimulates the pituitary to produce its own GH — it works upstream. Exogenous HGH (recombinant human growth hormone) bypasses the pituitary entirely and delivers GH directly. Key differences: sermorelin preserves hypothalamic-pituitary feedback (somatostatin still regulates output), produces pulsatile GH (more physiological), and carries lower theoretical risk of supraphysiological IGF-1 elevation. HGH provides more direct and controllable GH delivery but suppresses endogenous production.
Why was sermorelin withdrawn from the market?
Sermorelin (Geref) was voluntarily withdrawn from the US market in 2008 by its manufacturer, Serono, for commercial reasons — not due to safety concerns or FDA action. The withdrawal coincided with the broader availability of recombinant HGH products. Sermorelin remains available through licensed compounding pharmacies in the US and continues to be used clinically and studied in research settings.
Research GH-Axis Peptides at Purgo Labs
Sermorelin is not currently stocked — browse the closest available GHRH-class compounds.
How to Reconstitute Sermorelin
Sermorelin reconstitutes in bacteriostatic water (BAC water). For a 9mg vial, add 3mL BAC water for a 3mg/mL solution. Stable for 4 weeks refrigerated. Use a 27–31G insulin syringe for subcutaneous administration. Administer before sleep to align with natural GH pulsatility.